Drug

Pembrolizumab

Pembrolizumab: highest development phase Phase 3, developed by Celldex Therapeutics, Eli Lilly, GlaxoSmithKline and others. 22 trial records tracked on RxWires.

Highest phase: Phase 3
Developer: Celldex Therapeutics, Eli Lilly, GlaxoSmithKline

Trials

Drug	Phase	Indication
Pembrolizumab NCT04700124	Phase 3	Bladder Cancer
Pembrolizumab NCT06952504	Phase 3	Endometrial Cancer
Pembrolizumab NCT03361865	Phase 3	UC (Urothelial Cancer)
Pembrolizumab NCT03486873	Phase 3	Solid Tumors
Pembrolizumab NCT06216301	Phase 3	Metastatic Non-small Cell Lung Cancer
Pembrolizumab NCT05185739	Phase 2	Hepatocellular Carcinoma
Pembrolizumab NCT04704219	Phase 2	Renal Cell Carcinoma
Pembrolizumab NCT05565378	Phase 2	Lung Cancer, Non-Small Cell
Pembrolizumab NCT07021989	Phase 2	Hodgkin Lymphoma, Adult
Pembrolizumab NCT03248570	Phase 2	Castration Resistant Prostatic Cancer
Pembrolizumab NCT04040361	Phase 2	Non-small Cell Lung Cancer Stage IB
Pembrolizumab NCT02674061	Phase 2	Ovarian Neoplasms
Pembrolizumab NCT05255666	Phase 2	Triple Negative Breast Cancer
Pembrolizumab NCT02621151	Phase 2	Muscle-invasive Urothelial Cancer of the Bladder
Pembrolizumab NCT07808151	Phase 2	Colon Cancer
Pembrolizumab NCT06780111	Phase 1/2	Esophageal Squamous Cell Carcinoma
Pembrolizumab NCT03789097	Phase 1/2	Non-Hodgkin's Lymphoma
Pembrolizumab NCT04165070	Phase 1/2	Carcinoma, Non-Small-Cell Lung
Pembrolizumab NCT03267888	Phase 1/2	ISS Stage I Plasma Cell Myeloma
Pembrolizumab NCT04856189	Phase 1/2	Advanced Urothelial Carcinoma
Pembrolizumab NCT07020221	Phase 1/2	Pancreatic Ductal Adenocarcinoma
Pembrolizumab NCT03220477	Phase 1	Lung Cancer

Latest

No recent events.

Follow Pembrolizumab on RxWires to get trial status changes, FDA actions, filings and patent dates as they happen.

Follow free

Sourced from ClinicalTrials.gov, openFDA, SEC EDGAR and the FDA Orange Book. Not investment or medical advice.